Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.38 |
| ▸ | ESRRA | P11474 | 2/20 | 0.37 |
| ▸ | PNLIP | P16233 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242192 | 0.86 | PDE7A (0.52) | PDE7A | |
| SCHEMBL4228537 | 0.85 | MAPT (0.37) | HTR2ASLC6A4KCNH2PPARG | |
| SCHEMBL4238713 | 0.85 | PARP10 (0.41) | SCN9ASOS1 | |
| SCHEMBL4233643 | 0.81 | KDM4E (0.36) | HTR2ASLC6A4SCN9A | |
| SCHEMBL4228783 | 0.81 | PKM (0.41) | ESRRAPNLIP | |
| SCHEMBL4238402 | 0.76 | TBXA2R (0.39) | PDE7A | |
| SCHEMBL4232011 | 0.76 | HSPB1 (0.39) | PDE7A | |
| SCHEMBL4232519 | 0.75 | TDP1 (0.37) | — | |
| SCHEMBL4237839 | 0.75 | ALDH1A1 (0.44) | — | |
| SCHEMBL27831631 | 0.74 | NR1H4 (0.39) | HTR2ASLC6A4KCNH2EPHX2NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HTR2A 126/4885SLC6A4 438/4885SCN9A 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.